BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15075086)

  • 1. Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely.
    Martinelli G; Rondoni M; Buonamici S; Ottaviani E; Piccaluga PP; Malagola M; Baccarani M
    Haematologica; 2004 Apr; 89(4):495-7. PubMed ID: 15075086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
    Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
    Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFbeta/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely.
    Martinelli G; Buonamici S; Visani G; Malagola M; Piccaluga PP; Isidori A; Bosi C; Bonifazi F; Soverini S; Terragna C; Amabile M; Giannini B; Baccarani M
    Leukemia; 2003 Mar; 17(3):650-1; author reply 651-2. PubMed ID: 12646962
    [No Abstract]   [Full Text] [Related]  

  • 4. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
    Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
    Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFbeta/MYH11 transcript.
    Martinelli G; Ottaviani E; Testoni N; Montefusco V; Pastano R; Tura S
    Haematologica; 2000 May; 85(5):552-5. PubMed ID: 10800179
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
    Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
    Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions.
    Laczika K; Mitterbauer G; Mitterbauer M; Knöbl P; Schwarzinger I; Greinix HT; Rabitsch W; Fonatsch C; Mannhalter C; Lechner K; Jaeger U
    Leuk Lymphoma; 2001; 42(5):923-31. PubMed ID: 11697647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR.
    Krauter J; Hoellge W; Wattjes MP; Nagel S; Heidenreich O; Bunjes D; Ganser A; Heil G
    Genes Chromosomes Cancer; 2001 Apr; 30(4):342-8. PubMed ID: 11241787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two more inv(16) acute myeloid leukemia cases with infrequent CBFbeta-MYH11 fusion transcript: clinical and molecular findings.
    Martinelli G; Ottaviani E; Buonamici S; Isidori A; Malagola M; Piccaluga P; Baccarani M
    Haematologica; 2002 May; 87(5):554-5. PubMed ID: 12010674
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): a single-institution study of 224 Japanese AML patients.
    Monma F; Nishii K; Shiga J; Sugahara H; Lorenzo F; Watanabe Y; Kawakami K; Hosokai N; Yamamori S; Katayama N; Shiku H
    Leuk Res; 2007 Apr; 31(4):471-6. PubMed ID: 17052753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.
    Marcucci G; Caligiuri MA; Döhner H; Archer KJ; Schlenk RF; Döhner K; Maghraby EA; Bloomfield CD
    Leukemia; 2001 Jul; 15(7):1072-80. PubMed ID: 11455976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
    J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia.
    Liu L; Yang L; Mi Y; Wang J; Li J; Zhang Y; Ma X; Qin T; Xu Z; Xiao Z
    Leuk Res; 2011 Aug; 35(8):1020-6. PubMed ID: 21296419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease in acute myeloid leukaemia.
    Liu Yin JA
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):119-35. PubMed ID: 11987920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of CBF beta-MYH11 fusion transcript and inv(16)(p13;q22) in acute myelomonocytic leukemia(M4) by RT-PCR and FISH].
    He K; Gu B; Cao Q
    Zhonghua Xue Ye Xue Za Zhi; 1998 Jan; 19(1):23-6. PubMed ID: 10921098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
    Perea G; Lasa A; Aventín A; Domingo A; Villamor N; Queipo de Llano MP; Llorente A; Juncà J; Palacios C; Fernández C; Gallart M; Font L; Tormo M; Florensa L; Bargay J; Martí JM; Vivancos P; Torres P; Berlanga JJ; Badell I; Brunet S; Sierra J; Nomdedéu JF;
    Leukemia; 2006 Jan; 20(1):87-94. PubMed ID: 16281071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia.
    Scholl C; Breitinger H; Schlenk RF; Döhner H; Fröhling S; Döhner K;
    Genes Chromosomes Cancer; 2003 Nov; 38(3):274-80. PubMed ID: 14506704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High concordance of karyotype analysis and RT-PCR for CBF beta/MYH11 in unselected patients with acute myeloid leukemia. A single center study.
    Mitterbauer M; Laczika K; Novak M; Mitterbauer G; Hilgarth B; Pirc-Danoewinata H; Schwarzinger I; Haas OA; Fonatsch C; Lechner K; Jaeger U
    Am J Clin Pathol; 2000 Mar; 113(3):406-10. PubMed ID: 10705822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocytic sarcoma of mesentery in acute myeloid leukemia with CBFB/MYH11 fusion gene but not inv(16) chromosome: case report and review of literature.
    Fujieda A; Nishii K; Tamaru T; Otsuki S; Kobayashi K; Monma F; Ohishi K; Nakase K; Katayama N; Shiku H
    Leuk Res; 2006 Aug; 30(8):1053-7. PubMed ID: 16504290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
    Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
    Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.